RxDoctor Payments Data

Robert Frank, MD

Otolaryngology · Hermitage, TNNPI 1750640512

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 155 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 12.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,123, 2.6 times the $438 reported in 2019.

$4,283in general payments, 2019–2025

Across 155 payments — averaging $27.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$550
  • Regeneron Healthcare Solutions, Inc.$541
  • Inspire Medical Systems, Inc.$477
  • GSK$455
  • Stryker$440
  • Integra Lifesciences Corporation$314
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$4,283100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,283 in reported general payments places this provider in the 80th percentile of 191 otolaryngology providers in Tennessee.

See all otolaryngology providers in Tennessee

Medicare billing

Part B allowed, 2024
$145,410
Medicare patients
390
Services billed
4,624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ipratropium Bromide117$3,383
Azelastine Hcl99$2,738
Epinephrine13$1,968
Fluticasone Propionate57$949
Famotidine83$727
Ofloxacin17$719
Mometasone Furoate11$638
Albuterol Sulfate HfaAlbuterol Sulfate26$555
Montelukast Sodium32$518
Prednisone41$385
Cefdinir19$378
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav28$307
Doxycycline Hyclate20$190
Omeprazole22$187
Mupirocin22$183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USAEpinephrine$54$1,96813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 191 otolaryngology providers in Tennessee.

Other otolaryngology in Hermitage

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →